Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Organon
Deal Size : Undisclosed
Deal Type : Demerger
Merck Announces Completion of Organon & Co. Spinoff
Details : Organon will pursue sustainable growth in Women’s Health led by patent-protected Nexplanon (etonogestrel implant) franchise and fueled by its leading contraceptive and fertility businesses. It expects to establish a leading position in Biosimilars focu...
Brand Name : Nexplanon
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 03, 2021
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Organon
Deal Size : Undisclosed
Deal Type : Demerger
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Financing
Details : Organon’s commercial strategy will center around Nexplanon (etonogestrel implant), its long-active reversible contraceptive, that delivered approximately $1.6 billion in global sales in 2020.
Brand Name : Nexplanon
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 03, 2021
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Zentiva
Deal Size : $2.2 million
Deal Type : Agreement
Mithra to Commercialize Myring In France, Poland And UK
Details : Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets.
Brand Name : Myring
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 06, 2020
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Zentiva
Deal Size : $2.2 million
Deal Type : Agreement
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Gynial
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mithra Pharmaceuticals and Gynial Sign Commercialization Agreement for Myring™ in Switzerland
Details : Under the terms of this agreement, Gynial will distribute Myring™ in Switzerland, where the Swiss contraceptive rings market is worth EUR 8 million per year.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 05, 2020
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Gynial
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Undisclosed
Deal Size : $9.0 billion
Deal Type : Demerger
Details : Merck will retain its current growth pillars of Oncology, Vaccines, Hospital and Animal Health and continue to invest in research and development of breakthrough innovations across all areas of science.
Brand Name : Nexplanon
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 05, 2020
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Undisclosed
Deal Size : $9.0 billion
Deal Type : Demerger
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Farmitalia
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mithra Signs LSA for Commercialization of Myring™ in Italy, the Third Biggest Worldwide Market
Details : Under the terms of the agreement, Farmitalia will distribute Myring™ in Italy, which is the third largest worldwide vaginal contraceptive ring market in terms of sales value and volume, after the US & Germany.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Farmitalia
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?